<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="542">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358864</url>
  </required_header>
  <id_info>
    <org_study_id>1220.7</org_study_id>
    <secondary_id>2010-021715-17</secondary_id>
    <nct_id>NCT01358864</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)</brief_title>
  <official_title>A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Austria: Medicines and Medical Devices Agency</authority>
    <authority>Belgium: Federal Agency for Medicinal and Health Products</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12
      or 24 weeks in combination with PegIFN/RBV given for 48 weeks as compared to PegIFN/RBV
      alone in chronic GT-1 hepatitis C virus infected patients who failed a prior PegIFN/RBV
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Virological Response 12 Weeks Post Treatment (SVR12)</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with sustained virological response (SVR12) 12 weeks post treatment defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)</measure>
    <time_frame>24 weeks post treatment, up to 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with virological response after 24 weeks of treatment discontinuation (SVR24) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment Success (ETS)</measure>
    <time_frame>Week 4 and Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with early Treatment Success (ETS) defined as a plasma HCV RNA level &lt;25 IU/mL (undetected or detected) at Week 4 and &lt;25 IU/mL (undetected) at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment (EoT) when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment (EoT) when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">678</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>BI 201335 once a day (QD) for 24 weeks</description>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon-alpha (IFN)</intervention_name>
    <description>Pegylated Interferon-alpha for 48 weeks</description>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin (RBV) for 24 or 48 weeks</description>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to BI201335 for 24 weeks</description>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to
             screening

          2. Confirmed prior virological failure with an approved dose of PegIFN/RBV

          3. Age 18 to 70 years,

          4. HCV RNA (RiboNucleic Acid) = 1,000 IU/mL at screening,

        Exclusion criteria:

          1. HCV infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency
             Virus (HIV) co-infection

          2. Evidence of acute or chronic liver disease due to causes other than chronic HCV
             infection,

          3. Decompensated liver disease, or history of decompensated liver disease,

          4. Body weight &lt; 40 or &gt; 125 kg,

          5. Clinical evidence of significant or unstable cardiovascular disease, chronic
             pulmonary disease, history or evidence of retinopathy or clinically significant
             ophthalmological disorder

          6. Pre-existing psychiatric condition that could interfere with the subject's
             participation in and completion of the study

          7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or G6PD
             deficit)

          8. Hemoglobin &lt; 12 g/dL for women and &lt; 13 g/dL for men

          9. Patients who have been previously treated with at least one dose of any antiviral or
             immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic
             HCV infection including and not restricted to protease or polymerase inhibitors,
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.7.0091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaiparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jette</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3316 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3317 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3315 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3318 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4913 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4918 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifu, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izunokuni, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-gun, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kofu, Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurashiki, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsuyama, Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Namegata, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishinomiya, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogaki, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omura, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omuta, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tanabe, Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyama,Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsu, Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsuchiura, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3509 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barreiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Majadahonda-Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vigo (Pontevedra)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 22, 2015</lastchanged_date>
  <firstreceived_date>May 23, 2011</firstreceived_date>
  <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
